Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: #2 Standard formula Clear all
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 24, 2026, 4:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Novel Approach To Improving Lactation Support With Mobile Health Technology

NCT03332108
View directory record Official record
Conditions
Breastfeeding, Feeding Behavior
Interventions
EpxBreastfeeding, Baby book survey
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Training Versus Standard Physical Therapy After Shoulder Stabilization Surgery

NCT05506072
View directory record Official record
Conditions
Anterior Shoulder Dislocation, Recurrent Shoulder Dislocation, Shoulder Subluxation, Surgery
Interventions
Blood flow restriction therapy, Standard Physical Thearapy
Other
Lead sponsor
Keller Army Community Hospital
Federal
Eligibility
17 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
West Point, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 2Phase 3 Interventional

Pediatric Oncology Nutrition Intervention Trial

NCT06175273
View directory record Official record
Conditions
Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
Interventions
Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care
Dietary Supplement · Drug · Other
Lead sponsor
Corey Hawes
Other
Eligibility
2 Years to 19 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Phase 2 Interventional

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

NCT06679829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Melphalan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional

Using Simplified Meal Boluses Versus Carbohydrate Counting in Adolescents With Hybrid Closed Loop Systems

NCT06575790
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Simple Meal Bolusing, Carbohydrate counting
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 26 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional

Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

NCT07271043
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
protein supplement
Dietary Supplement
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurobehavioral Changes Following Spaceflight Stressors

NCT07293494
View directory record Official record
Conditions
Stressor, Individual, Alcohol Impairment, Sleep Deprivation, Impairment, Cognitive
Interventions
Alcohol Administration, Sleep Deprivation, Control
Other · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Phase 2Phase 3 Interventional

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions
MitoQ, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants

NCT07096011
View directory record Official record
Conditions
Infant Body Composition and Metabolism, Metabolism, Energy Expenditure, Infant Formula, Human Milk, Breast Milk, Metabolic Flexibility
Interventions
Meal Test - Human Milk, Meal Test - Infant Formula
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
2 Weeks to 16 Weeks
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 24, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional

Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

NCT01300793
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, B-cell Lymphoma
Interventions
Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Sep 24, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional Results available

Oral Rehydration Therapy in Burn Patients

NCT02124265
View directory record Official record
Conditions
Burn Any Degree Involving 20-29 Percent of Body Surface, Burn Any Degree Involving 30-39 Percent of Body Surface, Burn Any Degree Involving 40-49 Percent of Body Surface, Burn Any Degree Involving 50-59 Percent of Body Surface, Burn Any Degree Involving 60-65 Percent of Body Surface, Fluid Resuscitation
Interventions
CeraLyte 90
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 3 Interventional

Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy

NCT00200148
View directory record Official record
Conditions
Pancreaticoduodenectomy, Hepatectomy
Interventions
Normovolemic Hemodilution (ANH), Standard of care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Early Phase 1 Interventional

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

NCT01174940
View directory record Official record
Conditions
Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions
extracorporeal photopheresis
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Not applicable Interventional

PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS

NCT05296096
View directory record Official record
Conditions
Muscle Loss, Protein, Mobility, Pediatric ALL
Interventions
Protein dosage and rehabilitation team delivered exercise prescription
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 2Phase 3 Interventional

Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital

NCT01766011
View directory record Official record
Conditions
Pre-term Infants
Interventions
study pre-term formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 21 Days
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Mobile, Alabama • South Bend, Indiana • Wichita, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Exercise Prescription in Cardiac Rehabilitation

NCT03925493
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Myocardial Infarction, Coronary Artery Bypass Graft
Interventions
Graded Exercise Stress test (GXT) with Target Heart Rate Range, Heart rate monitors
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 24, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

NCT03386214
View directory record Official record
Conditions
Myelofibroses
Interventions
Pevonedistat, Ruxolitinib, Peripheral blood draw, Skin biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

NCT00588094
View directory record Official record
Conditions
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 24, 2026, 4:08 PM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 4:08 PM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

NCT02978716
View directory record Official record
Conditions
Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
Interventions
Trilaciclib, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
35
States / cities
Tucson, Arizona • Burbank, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 24, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

NCT03990376
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Radioisotope I-131-labeled albumin
Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 24, 2026, 4:08 PM EDT